Clinical Trial

Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-12.
Trial Details
NCT Number NCT07707674
Lead Sponsor Evopoint Biosciences Inc.
Conditions Metastatic Pancreatic Cancer
Enrollment 24 participants
Start Date 2026-07-30
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22